Nature Communications (Jul 2017)
Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy
- Eunice E. To,
- Ross Vlahos,
- Raymond Luong,
- Michelle L. Halls,
- Patrick C. Reading,
- Paul T. King,
- Christopher Chan,
- Grant R. Drummond,
- Christopher G. Sobey,
- Brad R. S. Broughton,
- Malcolm R. Starkey,
- Renee van der Sluis,
- Sharon R. Lewin,
- Steven Bozinovski,
- Luke A. J. O’Neill,
- Tim Quach,
- Christopher J. H. Porter,
- Doug A. Brooks,
- John J. O’Leary,
- Stavros Selemidis
Affiliations
- Eunice E. To
- Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering & Health, RMIT University
- Ross Vlahos
- Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering & Health, RMIT University
- Raymond Luong
- Department of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University
- Michelle L. Halls
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University
- Patrick C. Reading
- Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity
- Paul T. King
- Monash Lung and Sleep, Department of Medicine, Monash Medical Centre, Monash University
- Christopher Chan
- Department of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University
- Grant R. Drummond
- Department of Physiology, Anatomy & Microbiology, School of Life Sciences, La Trobe University
- Christopher G. Sobey
- Department of Physiology, Anatomy & Microbiology, School of Life Sciences, La Trobe University
- Brad R. S. Broughton
- Department of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University
- Malcolm R. Starkey
- Priority Research Centre’s Grow Up Well and Healthy Lungs, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, and Hunter Medical Research Institute
- Renee van der Sluis
- The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital
- Sharon R. Lewin
- The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital
- Steven Bozinovski
- Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering & Health, RMIT University
- Luke A. J. O’Neill
- School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin
- Tim Quach
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University
- Christopher J. H. Porter
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University
- Doug A. Brooks
- School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, Division of Health Sciences, University of South Australia
- John J. O’Leary
- Discipline of Histopathology, School of Medicine, Trinity Translational Medicine Institute (TTMI)
- Stavros Selemidis
- Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering & Health, RMIT University
- DOI
- https://doi.org/10.1038/s41467-017-00057-x
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 17
Abstract
Production of reactive oxygen species is an ancient antimicrobial mechanism, but its role in antiviral defense in mammals is unclear. Here, To et al. show that virus infection activates endosomal NOX2 oxidase and restricts TLR7 signaling, and that an endosomal NOX2 inhibitor decreases viral pathogenicity.
